[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"valve-heart-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:valve-heart-disease":22},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,39,70,94,117,145,178,205,229],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":20,"conditions":21,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100644344","construction-of-a-prospective-cohort-database-for-the-perioperative-period-of-cardiac-surgery-100644344",false,"NCT07662317","Construction of a Prospective Cohort Database for the Perioperative Period of Cardiac Surgery","Inclusion Criteria:\n\n* Patients undergoing cardiac surgery from May 1, 2026 to December 31, 2031\n\nExclusion Criteria:\n\n* Refusal to provide informed consent","ALL",{"count":17,"type":18},10000,"ESTIMATED","OBSERVATIONAL","Cardiovascular disease (CVD) is the leading cause of global morbidity and mortality, with its prevalence increasing significantly from 1990 to 2019. Establishing a comprehensive cardiac surgery database is crucial for exploring perioperative prognostic factors and improving clinical outcomes.\n\nThis muti-center, prospective observational study aims to construct a prospective cohort database for perioperative cardiac surgery. We plan to enroll adult patients who undergo cardiac surgery with cardiopulmonary bypass at the Second Affiliated Hospital of Zhejiang University and other hospitals from May 1, 2026 to December 31, 2031. Multi-dimensional perioperative data, including laboratory tests, hemodynamics, intraoperative echocardiography, and perioperative medications, will be collected and integrated, along with epidemiological data, clinical diagnosis and treatment information, multimodal data, and follow-up outcomes. An interconnected big data sharing platform will also be built.\n\nThis database will provide a valuable resource for multi-level researches such as perioperative risk assessment, individualized prevention, precise diagnosis and treatment, and therapeutic efficacy monitoring. It will also help optimize surgical and perioperative management, improve the quality of cardiac surgery, and provide evidence for the refinement of China's healthcare system, ultimately enhancing perioperative safety and rehabilitation efficiency of patients.",[22,23,24,25],"Valve Heart Disease","Coronary Artery Disease","Coronary Heart Disease","Aortic Diseases","RECRUITING","2026-06-22",{"date":29,"type":30},"2026-06-23","ACTUAL",{"date":32,"type":18},"2026-06-25",{"date":34,"type":18},"2032-05-31",{"name":36,"class":37},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":15,"minAge":45,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":55,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":38},"100642433","effects-of-myofascial-release-on-cardiac-patients-after-median-sternotomy-100642433","NCT07649330","Effects of Myofascial Release on Cardiac Patients After Median Sternotomy","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Able to communicate verbally and follow instructions\n* Diagnosed by a physician with coronary artery disease, valvular disease, or aortic disease\n* Undergoing median sternotomy\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Presence of a cardiac pacemaker\n* Presence of a ventricular assist device (VAD)\n* Existing central nervous system disorders (e.g., hemorrhagic or ischemic stroke, spinal cord injury, traumatic brain injury)\n* Cognitive impairment or inability to understand\u002Ffollow instructions\n* Diagnosed with chronic obstructive pulmonary disease (COPD)\n* History of previous thoracic surgery\n* ICU stay longer than 14 days","18 Years",{"count":47,"type":18},50,"INTERVENTIONAL",[50],"NA","After deciding to join this study and signing the informed consent form, participants will undergo the following interventions:\n\nAll participants will receive a preoperative assessment (Tp) before surgery. Within five days after transferring from the ICU to the general ward, participants will receive a baseline assessment (T0). After completing seven sessions of myofascial release (MFR), a post-intervention assessment (T1) will be conducted.\n\nAssessments include maximum inspiratory pressure (MIP), maximum expiratory pressure (MEP), pulmonary function tests, mid- and lower-thoracic mobility, surface electromyography (sEMG) to measure diaphragmatic and sternocleidomastoid muscle activity, and pain scores. Pulmonary function tests include forced vital capacity (FVC), forced expiratory volume in one second (FEV1), FEV1\u002FFVC ratio, and maximum voluntary ventilation (MVV).\n\nParticipants will be randomly assigned to an intervention group or a control group. The intervention group will receive myofascial release therapy in addition to routine physical therapy in the general ward. Routine therapy includes daily physical therapy sessions such as out-of-bed activities, incentive spirometry training (Triflow), and functional exercises. The MFR intervention consists of three steps:\n\nThe therapist places both hands on the thoracic outlet, with the index and middle fingers above the clavicle.\n\nOne hand is placed on the anterior chest and the other hand parallel on the participant's back.\n\nBoth hands are placed on the anterolateral region of the thoracoabdominal diaphragm.\n\nDuring each step, participants are instructed to take 10 slow, deep breaths and direct airflow toward the therapist's hands. Each session lasts approximately 15 minutes, once daily, for seven sessions.\n\nThe control group will receive only routine physical therapy (out-of-bed activities, incentive spirometry, and functional exercises) without additional myofascial release therapy.",[53,54,22],"Aortic Aneurysm and Dissection","Coronary Artery Disease (CAD)",[56,57,23,58,59,60],"Median Sternotomy","Cardiac Surgery","Aortic Aneurysm","Aortic Dissection","Valvular Heart Disease","2026-06-09",{"date":63,"type":30},"2026-06-16",{"date":65,"type":30},"2026-03-25",{"date":67,"type":18},"2027-09",{"name":69,"class":37},"Siou-Pin Huang",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":15,"minAge":45,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":80,"conditions":81,"keywords":82,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":38},"100314641","post-operative-myocardial-incident--atrial-fibrillation-100314641","NCT03376165","Post-Operative Myocardial Incident & Atrial Fibrillation","Longitudinal Study of Patients Undergoing Cardiac Surgery or Implantation of a Percutaneous Valve Prosthesis","POMI-AF","Inclusion Criteria:\n\n* patients scheduled for cardiac surgery (coronary artery bypass graft surgery and\u002For valvular surgery) or transcatheter valve implantation\n\nExclusion Criteria:\n\n* pregnant woman\n* urgent surgery or intervention\n* not able to consent to the protocol",{"count":79,"type":18},1500,"To explore predictors of major cardio-vascular events after cardiac surgery and trans-catheter valve implantation with a specific interest in studying mechanisms linking pre-operative leukocyte, fat and myocardial phenotypes with post-intervention outcomes.",[22,23],[83,84],"prognosis","translational research","2026-05-11",{"date":87,"type":30},"2026-05-14",{"date":89,"type":30},"2018-01-30",{"date":91,"type":18},"2028-01",{"name":93,"class":37},"University Hospital, Lille",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":15,"minAge":45,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":38},"100372178","comparative-imaging-assessment-of-valvular-heart-disease-100372178","NCT04126018","Comparative Imaging Assessment of Valvular Heart Disease","Assessment of Left Ventricular Volumes and Strain and Assessment of Valvular Lesions Using Two- and Three-dimensional Echocardiography and Cardiac MRI, a Correlation Study","Inclusion Criteria:\n\n* Age 18-90 years of age\n* Suspected moderate or severe MR,AR or AS on the basis of prior known clinical history or clinical exam.\n* Suspected CRT \"non-responder\" with an implanted MRI compatible CRT device and reduced ejection fraction\n\nExclusion Criteria:\n\n* Acute traumatic cardiac injury\n* Aortic dissection or aortic root rupture\n* Congenital heart diseases such as patent ductus arteriosus, coarctation of aorta, ASD and VSD\n* Presence of A-V fistula or intracardiac shunts\n* Any contraindications to CMR\n* Moderate or severe dysfunction in multiple valves\n* Patients with significant claustrophobia","90 Years",{"count":103,"type":18},200,"The purpose of the study is to compare the various 2D and 3D methods of valvular heart disease quantification (Doppler, PISA, VCA, volumetric method) and strain with cardiac magnetic resonance (CMR) measurements of left and right ventricular systolic function strain and myocardial fibrosis assessment.",[22,106,107],"Aortic Stenosis","Aortic Regurgitation","2026-01-12",{"date":110,"type":30},"2026-01-13",{"date":112,"type":30},"2019-08-23",{"date":114,"type":18},"2027-12-31",{"name":116,"class":37},"The Cleveland Clinic",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":15,"minAge":124,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":48,"phases":127,"briefSummary":128,"conditions":129,"keywords":131,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":38},"100482175","use-of-artificial-intelligence-guided-echocardiography-to-assist-cardiovascular-patient-management-100482175","NCT05558605","Use of Artificial Intelligence-Guided Echocardiography to assIst cardiovascuLar Patient managEment","AGILE-Echo","Inclusion Criteria:\n\n* Age \\>45 years\n* eligible for Medicare\n* exercise intolerance or cardiovascular (CV) risk factors\n\nExclusion Criteria:\n\n* Known HF or HVD\n* situations where cardio-protection is already indicated (eg. known CAD)\n* comorbid conditions with life expectancy \\\u003C2 years\n* inability to provide written informed consent","45 Years",{"count":126,"type":18},612,[50],"Heart Failure and valvular heart disease are disproportionate problems in rural and remote Australia (RRA). Echocardiography is the best imaging investigation, and essential for management, but access to this essential test shows huge geographic variations, primarily because of dependence on expert acquisition. This trial seeks to demonstrate the effectiveness of artificial intelligence-based echocardiography for triage and management of patients with known or suspected heart disease in RRA.",[130,22],"Heart Failure",[132,133,134,135],"Artificial intelligence","Echocardiography","Heart failure","Valve disease","2025-10-16",{"date":138,"type":30},"2025-10-20",{"date":140,"type":30},"2023-02-24",{"date":142,"type":18},"2026-06-30",{"name":144,"class":37},"Baker Heart and Diabetes Institute",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":15,"minAge":152,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":155,"conditions":156,"keywords":159,"overallStatus":167,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":38},"100587626","frailty-classification-algorithm-for-the-corsano-cardiowatch-287-2-a-development-and-validation-study-100587626","NCT06930833","FRAILTY Classification Algorithm for the Corsano CARDIOWATCH 287-2: a Development and Validation Study","FRAILTY-CW2","Inclusion Criteria:\n\n* ≥ 70 years old\n* Be able to provide consent\n* Be scheduled to undergo one of the following procedures:\n\n  * Aortic valve replacement\n  * Mitral valve repair with MitraClip\n  * Implantation of a pacemaker\n  * Percutaneous coronary intervention (PCI)\n\nExclusion Criteria:\n\n* Unable to wear the Corsano CardioWatch 287-2 due to reasons such as allergic reactions, wounds, amputations etc.;\n* Unable or unwilling to sign informed consent;\n* Significant mental or cognitive impairment;\n* Cardiovascular disease where heart rate is not measurable (e.g. LVAD)","70 Years",{"count":154,"type":18},20,"The FRAILTY-CARDIOWATCH study is investigating how well the Corsano CardioWatch 287-2, a wrist-worn medical device, can classify frailty in patients. Frailty is a condition often seen in older adults, characterized by decreased strength, endurance, and overall health, which can make individuals more vulnerable to illness or injury. The goal of this study is to develop an algorithm that can accurately assess frailty using the device. In phase 1 of the study, data will be collected from patients aged 70 or older who are scheduled for heart-related procedures, such as valve replacements or pacemaker implantation.\n\nThe study aims to compare the frailty classifications of the CardioWatch with two established methods: the Geriatric 8 (G8) questionnaire and the FRAIL scale. It will also compare the CardioWatch with the 6-minute walk test. Patients will wear the CardioWatch for six days-three days before their procedure and three days after-and complete the G8, FRAIL, and 6-minute walk tests. The collected data will help develop and train the frailty classification algorithm.\n\nThe main focus is to evaluate how well the frailty classifications from the CardioWatch match those from the other tests. This research could potentially lead to a more accurate and continuous way to monitor frailty in patients using wearable technology.",[157,22,158],"Cardiac Arrythmias","Cardiac Ischemia",[160,161,162,163,164,165,166],"Frailty","6-minute walking test","G8-score","wristband","wearable","remote monitoring","cardiac surgical interventions","NOT_YET_RECRUITING","2025-04-16",{"date":170,"type":30},"2025-04-20",{"date":172,"type":18},"2025-05",{"date":174,"type":18},"2026-10",{"name":176,"class":177},"Corsano Health B.V.","INDUSTRY",{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":15,"minAge":45,"maxAge":4,"enrollmentInfo":185,"targetDuration":187,"studyType":19,"phases":4,"briefSummary":188,"conditions":189,"keywords":191,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":38},"100580539","characterization-of-patients-and-treatment-outcomes-in-severe-tricuspid-regurgitation-100580539","NCT06838611","ChAracterization of Patients and Treatment OUtcomes in Severe Tricuspid Regurgitation","CAPTURE","Inclusion Criteria:\n\n* tricuspid regurgitation\n* qualification for transcatheter tricuspid valve intervention\n\nExclusion Criteria:\n\n* tricuspid regurgitation qualified for surgical treatment\n* concomitant left heart valve disease qualified for surgical treatment\n* multivessel coronary artery disease qualified for coronary artery bypass grafting\n* lack of patient's consent to enter the registry",{"count":186,"type":18},300,"2 Years","The goal of this observational study is to characterize the population of patients qualified for transcatheter tricuspid valve interventions (TTVI). It is expected to:\n\n* Describe the profile of patients qualified for TTVI\n* Establish the most common causes for disqualification from TTVI\n* Evaluate the immediate and long-term efficacy of TTVI\n* Evaluate TTVI safety Participants will undergo a standard qualification procedure for TTVI and then will be subject to a follow-up consisting of clinical examination, echocardiography and laboratory testing.",[190,130,22],"Tricuspid Regurgitation",[192,193,194,195],"tricuspid regurgitation","transcatheter tricuspid interventions","transcatheter edge-to-edge repair","heart failure","2025-02-16",{"date":198,"type":30},"2025-02-20",{"date":200,"type":30},"2023-11-14",{"date":202,"type":18},"2028-07-01",{"name":204,"class":37},"Medical University of Warsaw",{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":15,"minAge":211,"maxAge":212,"enrollmentInfo":213,"targetDuration":4,"studyType":48,"phases":215,"briefSummary":216,"conditions":217,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":38},"100545863","allogeneic-valve-transplantation-100545863","NCT06387446","Allogeneic Valve Transplantation","Inclusion Criteria\n\n* Patients requiring aortic, pulmonary, mitral or tricuspid valve replacement.\n* Pediatric patients 30 days or older and \\\u003C 18 years, and adult patients 18-50 yrs.\n\n  o Particularly patients with significant growth potential\n* Insufficient options are available for valve replacement\n\n  o Patients at risk of immunogenic bio-prosthetic valve failure\n* Discussion with patient \u002Ffamily - option for durable valve rather than traditional prosthesis\n* ABO compatible\n* Patient and family able to travel to BCH within 48 hour time frame or within our organ procurement organization\n* Patients that are able to maintain follow-up at BCH during the duration of the study\n* Patients that are able to provide medical record authorization for 5 year follow-up\n\nExclusion Criteria\n\n* Age \\\u003C 30 days\n* Irreversible multisystem organ failure; or additive effects of the multiple systems affected making transplant survival unlikely\n* Progressive systemic disease with early mortality (genetic\u002Fmetabolic, idiopathic, syndromic)\n* Morbid obesity (BMI\\>35)\n* Diabetes mellitus with evidence of end-organ damage\n* Severe chromosomal, neurologic or syndromic abnormalities\n* Immunocompromised condition (DiGeorge, SCID etc.)\n* Active infection\n* History of endocarditis\n* HIV or chronic hepatitis B or C infection\n* Malignancy within 5 years prior to transplant\n* Severe renal or liver failure\n* Inadequate social support for post-transplant management\n* Recent history of illicit drug, tobacco or alcohol abuse despite trials\u002Fassistance to stop behavior\n* Evidence of large stroke with high risk for hemorrhagic conversion\n* Heart transplant recipient\n* Patients that are unable to follow-up during the initial 6 month window\n* Patients that are unable to provide medical record authorization for 5 years","30 Days","50 Years",{"count":214,"type":18},4,[50],"Valves will be taken from hearts donated by organ donors, and implanted into patients who need a new heart valve.",[22,218,219],"Valve Disease, Heart","Valve Disease, Aortic","2024-09-22",{"date":222,"type":30},"2024-09-24",{"date":224,"type":30},"2024-05-01",{"date":226,"type":18},"2027-06-01",{"name":228,"class":37},"Boston Children's Hospital",{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":235,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":15,"minAge":45,"maxAge":237,"enrollmentInfo":238,"targetDuration":4,"studyType":48,"phases":240,"briefSummary":241,"conditions":242,"keywords":244,"overallStatus":167,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":38},"100541644","transfusion-in-cardiac-valve-surgery-100541644","NCT06332547","Transfusion in Cardiac Valve Surgery","A Multicenter Prospective, Randomized Controlled Study of Different Transfusion Thresholds in Cardiac Valve Surgery","TICVS","Inclusion Criteria:\n\n* All cardiac valve surgical patients undergoing CPB, isolated valve procedures Informed consent obtained\n\nExclusion Criteria:\n\n* Pregnant or maternal women Age less than 18 years or more than 80 years Undergo coronary artery bypass or large cardiac vessels procedure Emergencies Have been attended other researches Unable to receive blood for religious reasons Drug addict or malignant tumor patient","80 Years",{"count":239,"type":18},1600,[50],"This prospective, randomized controlled study is aimed to figure out suitable transfusion threshold in patients undergoing cardiac valve surgery under cardiopulmonary bypass(CPB). Patients are randomly assigned to restrictive and liberal transfusion group and receive blood transfusion during and after surgery. Compare primary and secondary outcomes of two groups.",[243,22],"Cardiac Surgery With Cardiopulmonary Bypass",[245,246,247],"cardiac valve surgery","transfusion","transfusion threshold","2024-03-26",{"date":250,"type":30},"2024-03-27",{"date":252,"type":18},"2024-04-01",{"date":254,"type":18},"2027-12-30",{"name":256,"class":37},"Guangdong Provincial People's Hospital"]